Stay updated with breaking news from Recursion Pharmaceuticals. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report)’s share price fell 5.5% during trading on Wednesday . The stock traded as low as $8.45 and last traded at $8.50. 1,189,638 shares changed hands during trading, a decline of 81% from the average session volume of 6,164,144 shares. The stock had previously closed at $8.99. Wall […]
Humacyte (NASDAQ:HUMA – Get Free Report) and Recursion Pharmaceuticals (NASDAQ:RXRX – Get Free Report) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, profitability, earnings, dividends, risk and institutional ownership. Insider and Institutional Ownership 44.7% of Humacyte shares are […]
Recursion Pharmaceuticals, Inc. announced that Robert Hershberg, M.D., Ph.D, has been appointed the new Chair of the Board of the company, effective at the end of this term, as Martin Chavez exits...
"Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed.
Jim Cramer says Corning has "not been able to generate the kind of return that I've wanted"; calls Recursion a "terrific spec"